PCRX Pacira BioSciences, Inc.
USHealthcareAs of 2026-07-10 12:02
Why PCRX matters now
Pacira BioSciences, Inc. (PCRX) is a US stock in Healthcare. The latest InvestLog snapshot shows $25.32 with -0.73% on the session and $995.8M in market capitalization; recent performance reads 1-month +0.09% and YTD -13.72%.
The latest financial table shown here is Q1 2026, with revenue of $177.4M, net income of $2.9M, and EPS of $0.07. Investors can compare that operating picture with valuation signals such as P/E 137.80 and FCF yield 15.1%.
The latest indexable market news headline is "Pacira BioSciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)" from GlobeNewsWire.
Additional event context on this page matters because analyst consensus is Hold with a median target of $32.00; recent insider activity includes RIKER LAUREN filing S-Sale. These signals are research inputs, not a recommendation.
Valuation
P/E (TTM)
137.80
PEG
1.29
P/B
1.38
P/S
1.20
EV/EBITDA
9.67
DCF Value
$343.12
FCF Yield
15.1%
Div Yield
0.0%
Margins & Returns
Gross Margin
79.3%
Operating Margin
3.1%
Net Margin
0.7%
ROE
0.7%
ROA
0.4%
ROIC
0.8%
Financials
| Period | Revenue | Net Income | EPS |
|---|---|---|---|
| Q1 2026 | $177.4M | $2.9M | $0.07 |
| Q4 2025 | $196.9M | $1.6M | $0.04 |
| FY 2025 | $726.4M | $7.0M | $0.16 |
| Q3 2025 | $179.5M | $5.4M | $0.12 |
Analyst Ratings
Consensus
Hold
Target (Consensus)
$32.00
Target (Median)
$32.00
Target Range
$32.00 - $32.00
Trading Activity
Insider Trades
Related Stocks
Latest News
Company Info
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
Country
US
Exchange
—
Beta
0.29
Operating within the United States, Pacira BioSciences, Inc. is dedicated to providing healthcare professionals and their patients with non-opioid solutions for pain management and regenerative health. Its offerings include EXPAREL, an injectable liposomal bupivacaine suspension, and ZILRETTA, an extended-release injectable suspension of triamcinolone acetonide. Furthermore, the company offers the iovera system, a non-opioid, handheld cryoanalgesia device capable of delivering precisely controlled cold temperatures to targeted nerves. Pacira also develops its unique multivesicular liposome (MVL) drug delivery technology, which encapsulates therapeutic compounds while preserving their inherent molecular structure. Established in 2006, the firm was formerly known as Pacira Pharmaceuticals, Inc. until its name change to Pacira BioSciences, Inc. in April 2019. Its main corporate office is situated in Tampa, Florida.